The synthetic estrogen diethylstilbestrol (DES) was widely prescribed in the 1940s, '50s, and '60s to prevent miscarriage and premature delivery. Its dangers were first revealed in the early 1970s, when Harvard-affiliated researchers linked the drug to a rare cancer of the vagina and cervix in the daughters of women who took DES while pregnant. In 1971, the FDA issued a warning against its use by pregnant women, but five to 10 million pregnant women and their babies had already been exposed. In the following decades, many other health problems were discovered among DES daughters and have been documented in a follow-up study.
To continue reading this article, you must login
Subscribe to Harvard Health Online for immediate access to health news and information from Harvard Medical School.